实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (2): 235-238.doi: 10.3969/j.issn.1672-5069.2022.02.021

• 非酒精性脂肪性肝病 • 上一篇    下一篇

黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎患者中医症候积分和肠道菌群平衡的影响*

王芳, 高晓霞, 汪庆强   

  1. 719000 陕西省榆林市第二医院消化内科(王芳);第一医院消化内科(高晓霞);空军军医大学第一附属医院消化内科(汪庆强)
  • 收稿日期:2021-04-29 出版日期:2022-03-10 发布日期:2022-03-15
  • 通讯作者: 高晓霞,E-mail:gxxns@126.com
  • 作者简介:王芳,女,42岁,大学本科,副主任医师。E-mail:ylwangfang@163.com
  • 基金资助:
    *陕西省科技厅科研基金资助项目(编号:2019-211)

Short-term efficacy of Huanglian Jiedu decoction and probiotics supplement in intervention of patients with non-alcoholic steatohepatitis

Wang Fang, Gao Xiaoxia, Wang Qingqiang   

  1. Department of Gastroenterology, Second Hospital, Yulin 719000, Shaanxi Province, China
  • Received:2021-04-29 Online:2022-03-10 Published:2022-03-15

摘要: 目的 研究黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎(NASH)患者中医症候积分和肠道菌群平衡的影响。方法 2018年12月~2020年6月我院收治的72例NASH患者,其中35例对照组在饮食控制和运动指导干预的基础上,接受双歧杆菌三联活菌制剂口服,另37例观察组在上述治疗的基础上接受黄连解毒汤治疗,均治疗观察12周。使用Fibroscan检测肝脏受控衰减参数(CAP),计算脂肪肝指数(FLI),采用平板菌落计数法检测每克粪便所含的细菌计数。结果 在治疗12 w末,观察组胁肋胀痛、脘腹胀满、周身困重和口干口苦中医症候积分分别为(1.4±0.6)分、(0.7±0.4)分、(1.2±0.6)分和(1.0±0.5)分,显著低于对照组[分别为(1.8±0.8)分、(1.3±0.6)分、(1.8±0.9)分和(1.5±0.6)分,P<0.05];观察组空腹血糖、HOMA-IR、血清TC、LDL-C水平分别为(5.4±0.7)mmol/L、(4.1±0.7)、(4.7±1.1)mmol/L和(2.6±0.8)mmol/L,显著低于对照组[分别为(5.8±0.9)mmol/L、(4.9±0.8)、(5.6±1.3)mmol/L和(3.1±0.9)mmol/L,P<0.05];观察组血清ALT和AST水平分别为(47.2±7.4)U/L和(43.5±6.2)U/L,显著低于对照组[(62.3±8.1)U/L和(57.9±8.4)U/L,P<0.05];观察组体质指数、CAP和FLI水平分别为(25.1±2.0)kg/m2、(252.6±12.7)db/m和(19.8±4.7),显著低于对照组[分别为(28.1±2.0)kg/m2、(261.1±15.2)db/m和(22.9±4.2),P<0.05];观察组粪肠杆菌计数为(7.4±0.9)CFU/g,显著低于对照组[(8.1±1.0)CFU/g,P<0.05],而拟杆菌和双歧杆菌计数分别为(8.3±1.1)CFU/g和(8.9±1.0)CFU/g,显著高于对照组[分别为(7.6±1.2)CFU/g和(8.0±0.9)CFU/g,P<0.05]。结论 应用黄连解毒汤联合益生菌制剂可有效改善NASH患者临床证候,调节糖脂代谢,改善肠道菌群平衡,短期改善肝功能指标,值得临床进一步验证。

关键词: 非酒精性脂肪性肝病, 黄连解毒汤, 益生菌, 中医症候积分, 肠道菌群平衡

Abstract: Objective The aim of this study was to investigate the short-term efficacy of Huanglian Jiedu decoction, a herbal medicine, and probiotics supplement in intervention of patients with non-alcoholic steatohepatitis (NASH). Methods 72 patients with NASH were enrolled in our hospital between December 2018 and June 2020, and we guided 35 patients in the control for appropriate sports and diet control and taking bifidobacterium triple viable, and other 37 patients received Huanglian Jiedu decoction at base of what in the control. The intervention in the two groups lasted for 12 weeks. The traditional Chinese medicine (TCM) symptoms scores were evaluated and blood biochemical indicators were routinely detected, including fasting blood glucose (FBG), fasting insulin (FINS), total cholesterol (TC ), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL) and albumin (ALB). The controlled attenuation parameters was detected by Fibroscan, the body mass index (BMI) and fatty liver index (FLI) were calculated, and intestinal flora examination was performed. Results At the end of week 12 of treatment, the scores of TCM syndromes of distending pain in hypochondrium, abdominal fullness and distention, uncomfortable body and sleepiness, and dry mouth and bitter taste in the observation group were(1.4±0.6),(0.7±0.4), (1.2±0.6) and (1.0±0.5), all significantly lower than [(1.8±0.8),(1.3±0.6),(1.8±0.9) and (1.5±0.6), respectively, P<0.05] in the control; the FBF, HOMA-IR, serum TC and LDL-C levels were (5.4±0.7)mmol/L, (4.1±0.7),(4.7±1.1)mmol/L and (2.6±0.8)mmol/L, all significantly lower than [(5.8±0.9)mmol/L, (4.9±0.8), (5.6±1.3)mmol/L and (3.1±0.9)mmol/L, respectively, P<0.05] in the control; serum ALT and AST levels were (47.2±7.4)U/L and (43.5±6.2)U/L, both significantly lower than [(62.3±8.1)U/L and (57.9±8.4)U/L, respectively, P<0.05] in the control; the BMI, CAP and FLI were (25.1±2.0)kg/m2, (252.6±12.7)db/m and (19.8±4.7), significantly lower than [(28.1±2.0)kg/m2, (261.1±15.2)db/m and (22.9±4.2), respectively, P<0.05] in the control; the fecal Enterobacter counts was (7.4±0.9)CFU/g, significantly lower than [(8.1±1.0)CFU/g, P<0.05], while the fecal Bacteroides and Bifidobacterium counts were (8.3±1.1)CFU/g and (8.9±1.0)CFU/g, both significantly higher than [(7.6±1.2)CFU/g and (8.0±0.9)CFU/g, respectively, P<0.05] in the control. Conclusion The application of Huanglian Jiedu decoction and probiotics supplement for patients with NASH could efficiently improve the TCM syndrome evaluation, which might be related to the regulation of glucolipid metabolism and improvement of intestinal flora balance.

Key words: Non-alcoholic steatohepatitis, Huanglian Jiedu decoction, Probiotics, TCM syndromes scores, Intestinal flora